-
1
-
-
53549107437
-
-
American Cancer Society, Atlanta: American Cancer Society;
-
American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society; 2008.
-
(2008)
Cancer facts and figures
-
-
-
4
-
-
14644399717
-
Hepsin paradox reveals unexpected complexity of metastatic process
-
Vasioukhin V. Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle 2004;3:1394-7.
-
(2004)
Cell Cycle
, vol.3
, pp. 1394-1397
-
-
Vasioukhin, V.1
-
6
-
-
0035423118
-
Expression profiling reveals hepsin overexpression in prostate cancer
-
Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61:5692-6.
-
(2001)
Cancer Res
, vol.61
, pp. 5692-5696
-
-
Magee, J.A.1
Araki, T.2
Patil, S.3
-
7
-
-
0035939903
-
Delineation of prognostic biomarkers in prostate cancer
-
Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
-
(2001)
Nature
, vol.412
, pp. 822-826
-
-
Dhanasekaran, S.M.1
Barrette, T.R.2
Ghosh, D.3
-
8
-
-
0035174607
-
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia
-
Stamey TA, Warrington JA, Caldwell MC, et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 2001;166:2171-7.
-
(2001)
J Urol
, vol.166
, pp. 2171-2177
-
-
Stamey, T.A.1
Warrington, J.A.2
Caldwell, M.C.3
-
9
-
-
0030850099
-
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer
-
Tanimoto H, Yan Y, Clarke J, et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 1997;57:2884-7.
-
(1997)
Cancer Res
, vol.57
, pp. 2884-2887
-
-
Tanimoto, H.1
Yan, Y.2
Clarke, J.3
-
10
-
-
0032040383
-
Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma
-
Zacharski LR, Ornstein DL, Memoli VA, Rousseau SM, Kisiel W. Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma. Thromb Haemost 1998;79:876-7.
-
(1998)
Thromb Haemost
, vol.79
, pp. 876-877
-
-
Zacharski, L.R.1
Ornstein, D.L.2
Memoli, V.A.3
Rousseau, S.M.4
Kisiel, W.5
-
11
-
-
5144225237
-
Hepsin promotes prostate cancer progression and metastasis
-
Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004;6:185-95.
-
(2004)
Cancer Cell
, vol.6
, pp. 185-195
-
-
Klezovitch, O.1
Chevillet, J.2
Mirosevich, J.3
Roberts, R.L.4
Matusik, R.J.5
Vasioukhin, V.6
-
12
-
-
0036894486
-
HEPSIN inhibits cell growth/invasion in prostate cancer cells
-
Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002;62:6812-6.
-
(2002)
Cancer Res
, vol.62
, pp. 6812-6816
-
-
Srikantan, V.1
Valladares, M.2
Rhim, J.S.3
Moul, J.W.4
Srivastava, S.5
-
13
-
-
33750156940
-
Pro-urokinase-type plasminogen activator is a substrate for hepsin
-
Moran P, Li W, Fan B, Vij R, Eigenbrot C, Kirchhofer D. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 2006;281:30439-46.
-
(2006)
J Biol Chem
, vol.281
, pp. 30439-30446
-
-
Moran, P.1
Li, W.2
Fan, B.3
Vij, R.4
Eigenbrot, C.5
Kirchhofer, D.6
-
14
-
-
15544386767
-
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2
-
Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 2005;579:1945-50.
-
(2005)
FEBS Lett
, vol.579
, pp. 1945-1950
-
-
Kirchhofer, D.1
Peek, M.2
Lipari, M.T.3
Billeci, K.4
Fan, B.5
Moran, P.6
-
15
-
-
33846415469
-
Protease inhibitors and their peptidomimetic derivatives as potential drugs
-
Fear G, Komarnytsky S, Raskin I. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol Ther 2007;113:354-68.
-
(2007)
Pharmacol Ther
, vol.113
, pp. 354-368
-
-
Fear, G.1
Komarnytsky, S.2
Raskin, I.3
-
16
-
-
33845339435
-
Protease inhibitors in the clinic
-
Abbenante G, Fairlie DP. Protease inhibitors in the clinic. Med Chem 2005;1:71-104.
-
(2005)
Med Chem
, vol.1
, pp. 71-104
-
-
Abbenante, G.1
Fairlie, D.P.2
-
17
-
-
12444316010
-
The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain
-
Somoza JR, Ho JD, Luong C, et al. The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain. Structure 2003;11:1123-31.
-
(2003)
Structure
, vol.11
, pp. 1123-1131
-
-
Somoza, J.R.1
Ho, J.D.2
Luong, C.3
-
18
-
-
0033003760
-
A simple statistical parameter for use in evaluation and validation of high throughput screening assays
-
Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
-
(1999)
J Biomol Screen
, vol.4
, pp. 67-73
-
-
Zhang, J.H.1
Chung, T.D.2
Oldenburg, K.R.3
-
19
-
-
0030835791
-
The crystal structure of human α-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor
-
Chirgadze NY, Sall DJ, Klimkowski VJ, et al. The crystal structure of human α-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor. Protein Sci 1997;6:1412-7.
-
(1997)
Protein Sci
, vol.6
, pp. 1412-1417
-
-
Chirgadze, N.Y.1
Sall, D.J.2
Klimkowski, V.J.3
-
20
-
-
0034064021
-
Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428
-
Evans DM, Sloan-Stakleff K. Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428. Am Surg 2000;66:460-4.
-
(2000)
Am Surg
, vol.66
, pp. 460-464
-
-
Evans, D.M.1
Sloan-Stakleff, K.2
-
21
-
-
0029931241
-
Anti-psoriatic drug anthralin activates transcription factor NF-κB in murine keratinocytes
-
Schmidt KN, Podda M, Packer L, Baeuerle PA. Anti-psoriatic drug anthralin activates transcription factor NF-κB in murine keratinocytes. J Immunol 1996;156:4514-9.
-
(1996)
J Immunol
, vol.156
, pp. 4514-4519
-
-
Schmidt, K.N.1
Podda, M.2
Packer, L.3
Baeuerle, P.A.4
-
22
-
-
0026550890
-
Characterization of specific proteases associated with the surface of human skin fibroblasts, and their modulation in pathology
-
Raynaud F, Bauvois B, Gerbaud P, Evain-Brion D. Characterization of specific proteases associated with the surface of human skin fibroblasts, and their modulation in pathology. J Cell Physiol 1992;151:378-85.
-
(1992)
J Cell Physiol
, vol.151
, pp. 378-385
-
-
Raynaud, F.1
Bauvois, B.2
Gerbaud, P.3
Evain-Brion, D.4
-
23
-
-
0025305869
-
Murine thymocytes possess specific cell surface-associated exoaminopeptidase activities: Preferential expression by immature CD4-8- subpopulation
-
Bauvois B. Murine thymocytes possess specific cell surface-associated exoaminopeptidase activities: preferential expression by immature CD4-8- subpopulation. Eur J Immunol 1990;20:459-68.
-
(1990)
Eur J Immunol
, vol.20
, pp. 459-468
-
-
Bauvois, B.1
-
24
-
-
0026566131
-
Human U937 cell surface peptidase activities: Characterization and degradative effect on tumor necrosis factor-a
-
Bauvois B, Sanceau J, Wietzerbin J. Human U937 cell surface peptidase activities: characterization and degradative effect on tumor necrosis factor-a. Eur J Immunol 1992;22:923-30.
-
(1992)
Eur J Immunol
, vol.22
, pp. 923-930
-
-
Bauvois, B.1
Sanceau, J.2
Wietzerbin, J.3
-
25
-
-
0034486945
-
Imaging proteolysis by living human breast cancer cells
-
Sameni M, Moin K, Sloane BF. Imaging proteolysis by living human breast cancer cells. Neoplasia 2000;2:496-504.
-
(2000)
Neoplasia
, vol.2
, pp. 496-504
-
-
Sameni, M.1
Moin, K.2
Sloane, B.F.3
-
26
-
-
0034282726
-
The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin
-
McGowen R, Biliran H, Jr., Sager R, Sheng S. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res 2000;60:4771-8.
-
(2000)
Cancer Res
, vol.60
, pp. 4771-4778
-
-
McGowen, R.1
Biliran Jr., H.2
Sager, R.3
Sheng, S.4
-
27
-
-
0035992779
-
Reversible and covalent binding of drugs to human serum albumin: Methodological approaches and physiological relevance
-
Bertucci C, Domenici E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr Med Chem 2002;9:1463-81.
-
(2002)
Curr Med Chem
, vol.9
, pp. 1463-1481
-
-
Bertucci, C.1
Domenici, E.2
-
28
-
-
37749000841
-
Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: Implications for drug discovery
-
Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov 2008;7:84-99.
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 84-99
-
-
Wasan, K.M.1
Brocks, D.R.2
Lee, S.D.3
Sachs-Barrable, K.4
Thornton, S.J.5
-
30
-
-
0022449003
-
Comparison of gas chromatography and high-performance liquid chromatography for the analysis of probucol in plasma
-
Satonin DK, Coutant JE. Comparison of gas chromatography and high-performance liquid chromatography for the analysis of probucol in plasma. J Chromatogr 1986;380:401-6.
-
(1986)
J Chromatogr
, vol.380
, pp. 401-406
-
-
Satonin, D.K.1
Coutant, J.E.2
-
31
-
-
3142709408
-
Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation
-
Wu CA, Tsujita M, Hayashi M, Yokoyama S. Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation. J Biol Chem 2004;279:30168-74.
-
(2004)
J Biol Chem
, vol.279
, pp. 30168-30174
-
-
Wu, C.A.1
Tsujita, M.2
Hayashi, M.3
Yokoyama, S.4
-
32
-
-
0028031605
-
MDL 29311, an analog of probucol, decreases triglycerides in rats by increasing hepatic clearance of very-low-density lipoprotein
-
Sheetz MJ, Barnhart RL, Jackson RL, Robinson KM. MDL 29311, an analog of probucol, decreases triglycerides in rats by increasing hepatic clearance of very-low-density lipoprotein. Metabolism 1994;43:233-40.
-
(1994)
Metabolism
, vol.43
, pp. 233-240
-
-
Sheetz, M.J.1
Barnhart, R.L.2
Jackson, R.L.3
Robinson, K.M.4
-
33
-
-
0037417930
-
Effects of AGI-1067 and probucol after percutaneous coronary interventions
-
Tardif JC, Gregoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-8.
-
(2003)
Circulation
, vol.107
, pp. 552-558
-
-
Tardif, J.C.1
Gregoire, J.2
Schwartz, L.3
|